HCA
ALXN

Harbour Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Harbour Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-4,300
Closed -$538K – 249
2018
Q2 		$538K Sell
4,300
-300
-7% -$35.1K 0.23% 123
2018
Q1 		$513K Buy
4,600
+1,700
+59% +$203K 0.22% 134
2017
Q4 		$347K Buy
+2,900
New +$353K 0.14% 166
2017
Q2 		– Sell
-3,520
Closed -$427K – 621
2017
Q1 		$427K Buy
3,520
+1,075
+44% +$139K 0.19% 138
2016
Q4 		$299K Hold
2,445
– – 0.21% 138
2016
Q3 		$300K Buy
+2,445
New +$315K 0.19% 149

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harbour Capital Advisors's ALXN Position: Q3 2018 in Review

Harbour Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 4,300 shares — an estimated $538K sold.

Harbour Capital Advisors first reported a position in ALXN in Q3 2016 and held it in 6 quarters. The position peaked at $538K in Q2 2018. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Harbour Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Harbour Capital Advisors sold 4,300 Alexion Pharmaceuticals shares in Q3 2018, an estimated $538K.
  • Harbour Capital Advisors first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 6 quarters.
  • Harbour Capital Advisors's Alexion Pharmaceuticals position peaked at $538K in Q2 2018.
  • 584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Harbour Capital Advisors's 13F filing for Q3 2018, filed 7 Nov 2018.